Orbem Successfully Completed Series A Financing Round

Orbem has raised €30 million in a Series A financing round. Led by global venture capital firm 83North, the investment positions Orbem at the forefront of leveraging artificial intelligence to industrialise MRI technology and make it more accessible, cost-effective and efficient. New investor La Famiglia and existing investors also supported the round. Also among Orbem's investors are: Personio co-founders Hanno Renner, Roman Schumacher and Chief Operating Officer Jonas Rieke, former Zalando CEO Rubin Ritter, Forto co-founders Michael Wax, Erik Muttersbach and Chief Operating Officer Dr Michael Ardelt, Kinexon co-founders Dr Alexander Hüttenbrink and Dr Oliver Trinchera, and Celonis Co-Founder and CEO Bastian Nominacher.

Also Read: Gutsy Launched with $51 Million Financing

Orbem's Technology

Orbem's pioneering product, powered by AI-powered MRI technology, is capable of scanning a wide range of biological samples, including food products such as eggs and nuts, various plant species, construction materials such as timber and even the human body. This innovative solution eliminates the need for human intervention in MRI imaging as the AI system seamlessly takes over tasks traditionally performed by technicians and radiologists. As a result, MRI procedures are becoming several hundred times more cost-effective and faster. This makes them applicable in a wide range of previously untapped markets.

Orbem's accessible AI innovation for screening biological materials is poised to disrupt many industries, including agriculture, construction and healthcare. In agriculture, Orbem's non-invasive technology empowers farmers to grow resource-efficient, climate-resilient crops. It will also improve food chain safety through AI-powered MRI. In the construction industry, the technologies will ensure structural integrity in biodegradable materials, thus accelerating the green economy. Orbem's fast and cost-effective AI-powered MRI solutions will also revolutionise healthcare testing. It will make imaging accessible to everyone and enable people around the world to routinely monitor their health and prevent the spread of disease.